MA37645B1 - Formulations stabilisées contenant des anticorps anti-dll4 - Google Patents
Formulations stabilisées contenant des anticorps anti-dll4Info
- Publication number
- MA37645B1 MA37645B1 MA37645A MA37645A MA37645B1 MA 37645 B1 MA37645 B1 MA 37645B1 MA 37645 A MA37645 A MA 37645A MA 37645 A MA37645 A MA 37645A MA 37645 B1 MA37645 B1 MA 37645B1
- Authority
- MA
- Morocco
- Prior art keywords
- formulations containing
- containing anti
- antibody
- dll4 antibodies
- stabilized formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
La présente invention concerne des formulations pharmaceutiques comprenant un anticorps qui se lie spécifiquement à un ligand humain delta-like 4 (dll4). Lesdites formulations peuvent contenir, outre un anticorps anti-dll4, un tampon de phosphate, un co-solvant organique, un disaccharide, et un sel. Les formulations pharmaceutiques selon la présente invention présentent un degré substantiel de stabilité d'anticorps après stockage pendant plusieurs mois et après avoir été soumises à une contrainte thermique et à d'autres contraintes physiques.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261653478P | 2012-05-31 | 2012-05-31 | |
PCT/US2013/043516 WO2013181486A1 (fr) | 2012-05-31 | 2013-05-31 | Formulations stabilisées contenant des anticorps anti-dll4 |
Publications (3)
Publication Number | Publication Date |
---|---|
MA37645A2 MA37645A2 (fr) | 2016-08-31 |
MA37645A3 MA37645A3 (fr) | 2017-07-31 |
MA37645B1 true MA37645B1 (fr) | 2018-10-31 |
Family
ID=48670784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37645A MA37645B1 (fr) | 2012-05-31 | 2013-05-31 | Formulations stabilisées contenant des anticorps anti-dll4 |
Country Status (29)
Country | Link |
---|---|
US (1) | US9675692B2 (fr) |
EP (1) | EP2854849B1 (fr) |
JP (1) | JP6144758B2 (fr) |
KR (1) | KR20150033615A (fr) |
CN (1) | CN104349791A (fr) |
AR (1) | AR092325A1 (fr) |
AU (1) | AU2013267301B2 (fr) |
BR (1) | BR112014028997A2 (fr) |
CA (1) | CA2872275C (fr) |
CL (1) | CL2014003237A1 (fr) |
CO (1) | CO7151478A2 (fr) |
DK (1) | DK2854849T3 (fr) |
EA (1) | EA029779B1 (fr) |
ES (1) | ES2668900T3 (fr) |
HK (1) | HK1207305A1 (fr) |
IL (1) | IL235468A0 (fr) |
LT (1) | LT2854849T (fr) |
MA (1) | MA37645B1 (fr) |
MX (1) | MX357146B (fr) |
NO (1) | NO2887943T3 (fr) |
NZ (1) | NZ702288A (fr) |
PH (1) | PH12014502429A1 (fr) |
PL (1) | PL2854849T3 (fr) |
PT (1) | PT2854849T (fr) |
SG (1) | SG11201407171XA (fr) |
SI (1) | SI2854849T1 (fr) |
TW (1) | TWI609696B (fr) |
UY (1) | UY34842A (fr) |
WO (1) | WO2013181486A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR201818814T4 (tr) | 2009-10-16 | 2019-01-21 | Oncomed Pharm Inc | Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı. |
EP3485903B1 (fr) | 2011-09-23 | 2022-11-16 | Mereo BioPharma 5, Inc. | Agents de liaison à vegf/dll4 et leurs utilisations |
CA2966042A1 (fr) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Therapie combinee pour le traitement d'une maladie |
US20180200325A1 (en) * | 2014-11-18 | 2018-07-19 | Shionogi & Co., Ltd. | Stabilized peptide composition |
CN109071644B (zh) | 2015-09-23 | 2023-09-19 | 昂考梅德药品有限公司 | 治疗癌症的方法和组合物 |
US20210379186A1 (en) * | 2018-04-16 | 2021-12-09 | Merck Patent Gmbh | Additives for protein formulations to improve thermal stability |
PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
WO2022010988A1 (fr) * | 2020-07-08 | 2022-01-13 | Regeneron Pharmaceuticals, Inc. | Formulations stabilisées contenant des anticorps anti-ctla-4 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
US5016784A (en) | 1990-02-15 | 1991-05-21 | Dexus Research Inc. | Applicator for highly reactive materials |
AU2309692A (en) | 1991-07-03 | 1993-02-11 | Cryolife, Inc. | Method for stabilization of biomaterials |
JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
EP0852951A1 (fr) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux |
US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
ATE230277T1 (de) | 1997-06-13 | 2003-01-15 | Genentech Inc | Stabilisierte antikörperformulierung |
JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
US7001892B1 (en) | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
ES2644275T3 (es) | 2000-08-11 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Preparaciones estabilizadas que contienen anticuerpos |
PT1324776E (pt) | 2000-10-12 | 2009-12-23 | Genentech Inc | Formulações de proteína concentradas de viscosidade reduzida |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
JP4317010B2 (ja) | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ,インコーポレイティド | IgG抗体の安定な凍結乾燥医薬製剤 |
EP3578168A1 (fr) | 2002-02-14 | 2019-12-11 | Chugai Seiyaku Kabushiki Kaisha | Formulation de solutions contenant des anticorps comprenant un sucre comme stabilisant |
US20040191243A1 (en) | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
ZA200507757B (en) | 2003-04-04 | 2007-01-31 | Genentech Inc | High concentration antibody and protein formulations |
WO2005072772A1 (fr) | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Compositions pharmaceutiques |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP2586459B1 (fr) | 2005-03-25 | 2017-05-24 | Regeneron Pharmaceuticals, Inc. | Formulations antagonistes du VEGF |
US20080311078A1 (en) | 2005-06-14 | 2008-12-18 | Gokarn Yatin R | Self-Buffering Protein Formulations |
HUE053612T2 (hu) | 2006-06-16 | 2021-07-28 | Regeneron Pharma | Intravitreális bevitelre alkalmas VEGF-antagonista készítmények |
US20100129354A1 (en) | 2006-10-27 | 2010-05-27 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
TW201039854A (en) | 2009-03-06 | 2010-11-16 | Genentech Inc | Antibody formulation |
TR201818814T4 (tr) * | 2009-10-16 | 2019-01-21 | Oncomed Pharm Inc | Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı. |
CA2781467C (fr) | 2009-11-20 | 2015-10-13 | Biocon Limited | Formulations d'anticorps |
AU2011223919B2 (en) | 2010-03-02 | 2015-03-19 | Abbvie Inc. | Therapeutic DLL4 binding proteins |
SG189220A1 (en) * | 2010-10-06 | 2013-05-31 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
-
2013
- 2013-05-29 AR ARP130101868A patent/AR092325A1/es unknown
- 2013-05-30 TW TW102119047A patent/TWI609696B/zh not_active IP Right Cessation
- 2013-05-31 JP JP2015515218A patent/JP6144758B2/ja active Active
- 2013-05-31 US US13/906,479 patent/US9675692B2/en active Active
- 2013-05-31 ES ES13730702.1T patent/ES2668900T3/es active Active
- 2013-05-31 KR KR1020147035879A patent/KR20150033615A/ko not_active Application Discontinuation
- 2013-05-31 MX MX2014014363A patent/MX357146B/es active IP Right Grant
- 2013-05-31 CN CN201380028578.1A patent/CN104349791A/zh active Pending
- 2013-05-31 PT PT137307021T patent/PT2854849T/pt unknown
- 2013-05-31 UY UY0001034842A patent/UY34842A/es unknown
- 2013-05-31 WO PCT/US2013/043516 patent/WO2013181486A1/fr active Application Filing
- 2013-05-31 CA CA2872275A patent/CA2872275C/fr active Active
- 2013-05-31 BR BR112014028997A patent/BR112014028997A2/pt not_active IP Right Cessation
- 2013-05-31 DK DK13730702.1T patent/DK2854849T3/en active
- 2013-05-31 EP EP13730702.1A patent/EP2854849B1/fr active Active
- 2013-05-31 SG SG11201407171XA patent/SG11201407171XA/en unknown
- 2013-05-31 NZ NZ702288A patent/NZ702288A/en not_active IP Right Cessation
- 2013-05-31 SI SI201330979T patent/SI2854849T1/en unknown
- 2013-05-31 PL PL13730702T patent/PL2854849T3/pl unknown
- 2013-05-31 EA EA201492186A patent/EA029779B1/ru not_active IP Right Cessation
- 2013-05-31 AU AU2013267301A patent/AU2013267301B2/en active Active
- 2013-05-31 LT LTEP13730702.1T patent/LT2854849T/lt unknown
- 2013-05-31 MA MA37645A patent/MA37645B1/fr unknown
- 2013-08-23 NO NO13831626A patent/NO2887943T3/no unknown
-
2014
- 2014-10-29 PH PH12014502429A patent/PH12014502429A1/en unknown
- 2014-11-03 IL IL235468A patent/IL235468A0/en unknown
- 2014-11-27 CL CL2014003237A patent/CL2014003237A1/es unknown
- 2014-12-23 CO CO14281503A patent/CO7151478A2/es unknown
-
2015
- 2015-08-18 HK HK15108004.0A patent/HK1207305A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA37645B1 (fr) | Formulations stabilisées contenant des anticorps anti-dll4 | |
MA35904B1 (fr) | Formulations stabilisées contenant des anticorps anti-ang2 | |
Yewdell et al. | Original antigenic sin: how original? How sinful? | |
MA33993B1 (fr) | Formulations stabilisées contenant des anticorps contre le récepteur de l'interleukine-6 (il-6r) | |
MA35355B1 (fr) | Formulations stabilisées contenant des anticorps anti-pcsk9 | |
SG11201907321TA (en) | Anti-gprc5d antibody and molecule comprising the antibody | |
JP2007520566A5 (fr) | ||
TNSN07304A1 (en) | Combination of xolair with immunosuppressive agent | |
MX2019008084A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). | |
CY1113003T1 (el) | Ευσταθη παρασκευασματα laquinimod | |
IL194550A (en) | Isolated antibodies or their fragments that bind to human protein tyrosine phosphate in a cell, their pharmaceutical preparations and their use | |
JOP20190250A1 (ar) | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب | |
MY159156A (en) | Antibody formulation | |
EA200970469A1 (ru) | Антитела-агонисты рецептора trkb и их применение | |
FR18C1032I2 (fr) | Anticorps anti-fgf23 et composition pharmaceutique le comprenant | |
BRPI0508732A (pt) | composição de um produto de beleza para limpeza | |
EP4219560A3 (fr) | Anticorps neutralisant l'intégrine alpha v bêta 8 | |
MY185802A (en) | Antibody formulation | |
EP3941945A4 (fr) | Anticorps dirigés contre l'antigène trophoblaste 2 de surface cellulaire (trop2) et conjugués anticorps-médicament les comprenant | |
MX2021011137A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-il-33. | |
MA31014B1 (fr) | Vaccin contre la leishmania canine. | |
EA201070826A1 (ru) | Антитела против pcrv | |
UA109148C2 (uk) | Композиції на основі антитіла проти vegfr-3 | |
Lee et al. | Monoclonal Antibodies Attached to Carbon Nanotube Transistors for Paclitaxel Detection | |
TH154849A (th) | สูตรตำรับที่บรรจุแอนติบอดีต้าน-dll4 ที่ถูกเพิ่มความคงตัว |